FDA Accepts sBLA, Grants Priority Review to Liso-Cel in Pretreated MZL
Written by
Cancer Network
Published
0
comments
0
min
Results from the marginal zone lymphoma cohort of the TRANSCEND FL trial showed liso-cel elicited an ORR of 95.5% and a CR rate of 62.1%.